Literature DB >> 32269711

Adrenomedullin inhibits tumor metastasis and is associated with good prognosis in triple-negative breast cancer patients.

Li-Li Liu1,2, Shi-Lu Chen1,2, Yu-Hua Huang1,2, Xia Yang1,2, Chun-Hua Wang1,2, Jie-Hua He1,2, Jing-Ping Yun1,2, Rong-Zhen Luo1,2.   

Abstract

BACKGROUND: Cancer metastasis is the major reason for cancer-related deaths, but the mechanism of cancer metastasis still unclear. Adrenomedullin (ADM), a peptide hormone, functions as a local paracrine and autocrine mediator with multiple biological activities, such as angiogenesis, cell proliferation, and anti-inflammation. However, the expression and potential function of ADM in triple-negative breast cancer (TNBC) remain unclear.
METHODS: Real-time polymerase chain reaction and western blotting were performed to examine the expression of ADM in TNBC tissues and cell lines. A total of 458 TNBC tissue samples and adjacent nontumor tissue samples were detected by immunochemistry to determine the correlation between ADM expression and clinicopathological characteristics. We determined the role and mechanistic pathways of ADM in tumor metastasis in cell lines.
RESULTS: Our data showed that ADM expression was noticeably decreased in TNBC samples and cell lines. Low expression levels correlate with an increased risk of recurrence and metastasis. Furthermore, low ADM expression was associated with poor prognosis and was an independent marker for TNBC. In vitro, ADM may decrease cancer cell invasion, which is likely the result of its effect on the cancer cell epithelial-mesenchymal transition.
CONCLUSIONS: Our findings suggest that ADM is a valuable biomarker for TNBC prognosis and an anti-metastasis candidate therapeutic target in triple-negative breast cancer. AJTR
Copyright © 2020.

Entities:  

Keywords:  Adrenomedullin; epithelial-mesenchymal transition; triple-negative breast cancer patients

Year:  2020        PMID: 32269711      PMCID: PMC7137045     

Source DB:  PubMed          Journal:  Am J Transl Res        ISSN: 1943-8141            Impact factor:   4.060


  29 in total

Review 1.  Adrenomedullin - new perspectives of a potent peptide hormone.

Authors:  Ria Schönauer; Sylvia Els-Heindl; Annette G Beck-Sickinger
Journal:  J Pept Sci       Date:  2017-02-02       Impact factor: 1.905

2.  MYB Promotes Desmoplasia in Pancreatic Cancer through Direct Transcriptional Up-regulation and Cooperative Action of Sonic Hedgehog and Adrenomedullin.

Authors:  Arun Bhardwaj; Sanjeev K Srivastava; Seema Singh; Nikhil Tyagi; Sumit Arora; James E Carter; Moh'd Khushman; Ajay P Singh
Journal:  J Biol Chem       Date:  2016-05-31       Impact factor: 5.157

3.  Plasma Adrenomedullin and Allelic Variation in the ADM Gene and Kidney Disease in People With Type 2 Diabetes.

Authors:  Gilberto Velho; Stéphanie Ragot; Kamel Mohammedi; Elise Gand; Mathilde Fraty; Frédéric Fumeron; Pierre-Jean Saulnier; Naima Bellili-Munoz; Nadine Bouby; Louis Potier; François Alhenc-Gelas; Michel Marre; Samy Hadjadj; Ronan Roussel
Journal:  Diabetes       Date:  2015-05-06       Impact factor: 9.461

Review 4.  Regulation of cardiovascular development and homeostasis by the adrenomedullin-RAMP system.

Authors:  Takayuki Shindo; Megumu Tanaka; Akiko Kamiyoshi; Yuka Ichikawa-Shindo; Hisaka Kawate; Akihiro Yamauchi; Takayuki Sakurai
Journal:  Peptides       Date:  2018-04-22       Impact factor: 3.750

5.  Adrenomedullin interacts with VEGF in endometrial cancer and has varied modulation in tumours of different grades.

Authors:  J J Evans; K Chitcholtan; J M Dann; P Guilford; Gavin Harris; L K Lewis; J Nagase; A A W Welkamp; R Zwerus; P H Sykes
Journal:  Gynecol Oncol       Date:  2011-12-16       Impact factor: 5.482

6.  Molecular cloning and biological activities of rat adrenomedullin, a hypotensive peptide.

Authors:  J Sakata; T Shimokubo; K Kitamura; S Nakamura; K Kangawa; H Matsuo; T Eto
Journal:  Biochem Biophys Res Commun       Date:  1993-09-15       Impact factor: 3.575

7.  Adrenomedullin is a therapeutic target in colorectal cancer.

Authors:  Liangjing Wang; Manish Gala; Masayoshi Yamamoto; Maria S Pino; Hirotoshi Kikuchi; Daniel S Shue; Senji Shirasawa; Thomas R Austin; Maureen P Lynch; Bo R Rueda; Lawrence R Zukerberg; Daniel C Chung
Journal:  Int J Cancer       Date:  2013-11-07       Impact factor: 7.396

8.  The role of adrenomedullin in the pathogenesis of gastric cancer.

Authors:  Fuhao Qiao; Jian Fang; Jinfeng Xu; Wenqiu Zhao; Ying Ni; Bufugdi Andreas Akuo; Wei Zhang; Yun Liu; Fangfang Ding; Guanlin Li; Baoguo Liu; Hua Wang; Shihe Shao
Journal:  Oncotarget       Date:  2017-06-29

9.  ESMO 2018 presidential symposium-IMpassion130: atezolizumab+nab-paclitaxel in triple-negative breast cancer.

Authors:  Peter Schmid
Journal:  ESMO Open       Date:  2018-10-20

10.  Altered epidermal fatty acid-binding protein expression in hepatocellular carcinoma predicts unfavorable outcomes.

Authors:  Jia-Bin Lu; Shao-Hang Cai; Ying-Hua Pan; Jing-Ping Yun
Journal:  Cancer Manag Res       Date:  2018-11-23       Impact factor: 3.989

View more
  2 in total

1.  Intermedin (adrenomedullin 2) promotes breast cancer metastasis via Src/c-Myc-mediated ribosome production and protein translation.

Authors:  Lingmiao Kong; Ying Xiong; Denian Wang; Luping Huang; Min Li; Zhongxue Feng; Yue Zhou; Haili Zhang; Fei Liu; Fei Xiao; Yong'gang Wei; Wei Zhang
Journal:  Breast Cancer Res Treat       Date:  2022-07-28       Impact factor: 4.624

2.  Associations of Plasma Bioactive Adrenomedullin Levels with Cardiovascular Risk Factors in BRCA1/2 Mutation Carriers.

Authors:  Jacqueline Lammert; Maryam Basrai; Joachim Struck; Oliver Hartmann; Christoph Engel; Stephan C Bischoff; Anika Berling-Ernst; Martin Halle; Marion Kiechle; Sabine Grill
Journal:  Geburtshilfe Frauenheilkd       Date:  2022-06-03       Impact factor: 2.754

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.